Efficacy of Vitamin E Versus Pioglitazone in Treating Non-Alcoholic Fatty Liver Disease (NAFLD) without Diabetes “Decoding the Exodus of Liver Health”.
DOI:
https://doi.org/10.29309/TPMJ/2024.31.12.8405Keywords:
Efficacy, Non-alcoholic Fatty Liver Disease, Non-diabetics, Pioglitazone, Vitamin EAbstract
Objective: To compare the effectiveness of vitamin E in comparison with Pioglitazone in the management of NAFLD without Diabetes. Study Design: Randomized Control Trial. Setting: Outpatient Department of Allied Hospital, Faisalabad. Period: Dec 2023 to May 2024. Methods: The Ethics Review Committee of Faisalabad Medical University was taken on board and patients having the characteristics of the set Inclusion Criteria were enrolled as allowed. Selected individuals were counseled regarding the study and their consent was sought. Using a computer-generated random number table, two main groups were formed out of the participants, Group A and Group B. Group A was given 800IU of Vitamin E daily. Group B received Pioglitazone 30mg daily. Patients were monitored for efficacy over three months by tracking ALT levels as specified in the operational definition. Follow-up was ensured through contact numbers. Results: In our study of 722 cases (361 in each group), the mean age was 41.25±6.41 years in Group A and 41.23±6.56 years in Group B. Males comprised 60.11% (n=217) of Group A and 59.56% (n=215) of the Group B, while females accounted for 39.89% (n=144) out of Group A and 40.44% (n=146) of the Group B. Efficacy comparison showed that 49.72% (n=147) in Group A and 31.30% (n=113) in Group B achieved efficacy, with a p-value of 0.008, pointing out a considerable difference. Conclusion: Our study succeeded in establishing the better efficacy of Vitamin E in treating NAFLD compared to Pioglitazone.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 The Professional Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.